Abbott Expects Science To “Trump” Scale; Sees Industry In “Transformation”
Abbott's formula for navigating a period of "transformation" in the pharmaceutical industry includes focusing on therapeutic categories where science matters more than scale, CEO Miles White told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 3 in New York
You may also be interested in...
Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011